A two-part randomized placebo controlled double blind multicenter Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis (PBC).

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Primary Biliary Cholangitis (pbc)
    Cholestatic Pruritus
  • Age: Between 18 Year(s) - 80 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Participants who have proven PBC.
    2. A female participant is eligible to participate if she is not pregnant or breastfeeding, and is either a woman of non-childbearing potential or is a woman of childbearing potential using accepted

You may not be eligible for this study if the following are true:

    1. Participants with recent positive COVID-19 test results, symptoms suggestive of active COVID-19 infection (e.g. fever, loss of taste or smell, cough, shortness of breath) and/or contact within the past 14 days with someone with COVID-19 are ex


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.